Levi & Korsinsky reminds shareholders of Erasca, Inc. that August 10, 2026 is the deadline to seek lead plaintiff appointment in a securities class action. The lawsuit names CEO Jonathan Lim and CFO David Chacko as individual defendants, alleging they made misleading statements about the ERAS-0015 drug candidate. The class period runs from January 14, 2025 through April 26, 2026, during which the company's stock fell 53.9% after disclosures of patent infringement allegations and a patient death in trials. The complaint claims the officers signed false Sarbanes-Oxley certifications and were motivated to inflate the stock price to facilitate a $258.8 million offering that closed in January 2026.
Erasca IncSecurities class action lawsuit alleging misleading statements about drug candidate, with patent infringement and patient death disclosures.